Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Scott Bessent has given an update on the $2,000 stimulus checks President Donald Trump proposed paying out using the revenue raised from his tariffs. In an interview with ABC News on Sunday, the ...

Abstract: Java web applications have been extensively utilized for hosting and powering high-value commercial websites. However, their intricate complexities leave them susceptible to a critical ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

X has yet to give any official commentary regarding the issue, though its engineers have unofficially acknowledged the problem to the security researcher. But if you've been using X long enough, you ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...